Abstract:
Introduction:
Hepatitis C Infection is a major healthcare concern, affecting more than 185 million individuals worldwide (2.8% of world population), with prevalence ranging from 0.5% to nearly 18% in countries burdened with this spherical, single stranded RNA virus 1 . Prevalence of hepatitis C in Bangladesh is 0.8% 2 . Approximately 500,000 people succumb each year because of complications of HCV related chronic liver disease globally 3 . Moreover, a high percentage of chronicity (~85%) renders Hepatitis C a considerable disease burden, with 10-15% of them leading to cirrhosis of liver in 20 years. Newer Direct Acting Antiviral drugs in the battle against HCV infection have drawn great attention worldwide.
Being a blood-borne virus, it is most commonly transmitted among people who receive improperly screened blood or blood products or via sharing needles among IV drug abusers. Vertical and sexual transmissions are also possible but in a lesser amount.
Clinical course of the Disease:
HCV infection is completely asymptomatic in 60-70% cases despite a chronicity rate of around 85%. 10-15% of these chronic carriers will develop cirrhosis owing to disease process or various risk factors like alcohol consumption, co-infection with HIV/HBV and other comorbidities 4 . Compensated cirrhosis can progress to decompensation in 5% patients at 1 year, gradually increasing to 30% at 10 years from diagnosis. After decompensation 5 year survival rate comes down to 50% as compared to 91% in compensated cases 5, 6 . Once cirrhosis is established, hepatocellular carcinoma can occur at a rate of 1%-4% a year 4 .
In HBV infection, approximately 5% develop chronicity 7 and 10% of chronic infection 8 may need treatment. On the other hand, in HCV infection, 85% 8 develop chronicity and needs treatment. So, in terms of number of patients need to be treated, the bulk of chronic HCV patients outnumber chronic HBV patients.
Genotype Distribution:
HCV infection is variedly distributed throughout the world (fig:1), with Central Asia and Sub-Saharan Africa hit the most with prevalence of 5.4% and 5.3% respectively, with highest prevalent countries are Egypt (15%) and Mongolia (11%) 9 . Countries of the South East Asia are mostly among the low prevalence countries (<1%). The genotypic distribution plays a crucial role in planning management. Although Genotype 1 is most common worldwide, non-genotype 1 HCV cases still comprise over half of all HCV cases 10 . Genotype 3 is most prevalent in South Asia, Genotype 4 in Middle East, Egypt and Central Africa and Genotype 5 in South Africa 11, 12 .
Treatment Goal:
The goal of treating HCV is to eliminate the virus and if not possible, to delay its progression to prevent complications. Achievement of Sustained Virological Response (SVR) is considered as protection against progression of the disease and improvement in the clinical outcome. However relapses may occur due to persistence of HCV in liver or extra-hepatic tissues 14 . 
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Newer DAA:
The combination of Velpatasvir and Sofosbuvir is well on its way to be approved later this year, as a pangenotype drug, with special affinity towards Genotype 3 HCV infection.
Bangladesh and South Asia:
In Bangladesh, the results of Sofosbuvir use are promising. The patients who received Sofosbuvir containing regimens since February, 2015, along with Ribavirin and/or Peg-interferon, have mostly cleared Managing Genotype 3, which is more prevalent in this area and is difficult to treat, is proving to be a challenge [16] . Newer DAAs have overcome this problem. Other special population groups like End Stage Renal Disease with or without maintenance hemodialysis, HCV-HBV and HCV-HIV co-infection are also difficult to treat.
Barriers in access to treatment of HCV:
In Bangladesh, majority of HCV infected patients do not know they are infected due to lack of adequate screening program. Like the west, universal health care is not available here. Comprehensive insurance advantages are also absent. Different strategies to improve these barriers may be taken like identifying high risk groups, creating public awareness, making access to costly drugs, making tests for screening, confirmation, liver fibrosis more available and adequate monitoring .
Prevention:
Development of vaccine for HCV is yet not possible due to high genetic variability of the virus including presence of numerous quasispecies, limited animal models for research, difficulty enrolling at-risk people in vaccine trials and lack of a clear marker for protection. So, till now use of disposable syringes and needles, adequate sterilization of instruments, screening of blood and blood products and identification and treatment of carriers is the main mode of prevention.
Cost Considerations:
The initial high price of the DAAs has been mitigated by the introduction of generic products in developing countries. But the developed counties are still burdened with the same, even after government reimbursements.
Conclusion:
Due to availability of very effective oral medications with a high sustained virological response, scientists working in this field are hopeful to eradicate HCV infection from the planet in future. DAAs which are pan-genotypic are great hope in the management and eradication of hepatitis C. Properly addressing the global burden with appropriate management to combat HCV infection surely mark great advancement towards a newer and better future.
